Enhancing the Bioavailability of Low-Solubility Compounds
We respect your privacy, by clicking ‘Watch On-Demand’ you agree to having your details passed onto the sponsors who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
Low aqueous solubility resulting in poor oral bioavailability of drug candidates is recognised as an increasingly common challenge facing the pharmaceutical industry. An estimated 25% to 30% of compounds in early development have poor bioavailability due to low solubility, representing a significant loss in therapeutic and economic opportunity.
In this complimentary case study webcast, Bend Research discusses amorphous dispersion based formulations highlighting:
- Outlining the need for increased solubility and rapid absorption
- Assessing the impact of enteric dispersions on absorption rate
- Developing rapidly dissolving amorphous formulations
- Pursuing formulation and process development for amorphous drugpolymer nanoparticles
Presenters:
Dana Settell
Director of Business Development
Bend Research, Inc
We respect your privacy, by clicking ‘Watch On-Demand’ you agree to having your details passed onto the sponsors who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
